NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCEL stock has increased by 25.1% and is now trading at $15.11. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) posted its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.02. The biotechnology company had revenue of $26.70 million for the quarter, compared to the consensus estimate of $26.23 million. Vericel had a positive return on equity of 5.87% and a negative net margin of 9.39%. The business's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.07) earnings per share. View Vericel's earnings history.

5 Wall Street analysts have issued 12 month price objectives for Vericel's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Vericel's share price to reach $24.25 in the next twelve months. This suggests a possible upside of 60.5% from the stock's current price. View analysts' price targets for Vericel.

Media coverage about VCEL stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vericel earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the company's share price in the immediate future. View the latest news about Vericel.

Some companies that are related to Vericel include Denali Therapeutics (DNLI), Twist Bioscience (TWST), Alector (ALEC), Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), Beam Therapeutics (BEAM), I-Mab (BDTX), Sorrento Therapeutics (SRNE), Regenxbio (RGNX), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Cortexyme (CRTX) and NanoString Technologies (NSTG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $15.11.

Vericel has a market capitalization of $681.61 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]